Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 3157 versus placebo before HRV-16 inoculation in adults with mild to moderate asthma
NL-OMON39844Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing Placebo with CNTO 3157 (2 arms). Primary endpoints: Respiratory efficacy after HRV-16 inoculation, Daily asthma symptom assessments and 1 more. Started May 2013; status: active, not recruiting.
02
Drugs
CNTO3157
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON39844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39844.